---
title: "NHS National Generic Pharmaceuticals Transition 2021_1"
ocid: "ocds-h6vhtk-02aba8"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02aba8"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-02aba8.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-02aba8.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)"
published: "2021-04-29"
---

# NHS National Generic Pharmaceuticals Transition 2021_1

Buyer: THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)  
Current stage: Award  
OCID: ocds-h6vhtk-02aba8

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02aba8)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-02aba8.json)

## Summary

The NHS Commissioning Board, operating as NHS England, initiated a tender titled "NHS National Generic Pharmaceuticals Transition 2021_1", primarily focused on pharmaceutical products under the goods category. The procurement process is currently in the awarded stage, following an open procedure and was executed in the UK. The framework agreement has a total maximum duration of 29 months, with provisions for call-offs commencing from April 15, 2021, up to June 30, 2022, depending on the specific regional lots. Key aspects include potential extensions at the buyer's discretion and an emphasis on various award criteria beyond just price.

This tender presents significant growth opportunities for businesses within the pharmaceutical sector, particularly for SMEs that can supply both transition and various medicinal products. Companies with capabilities in manufacturing, distributing, or providing pharmaceutical products are well-positioned to compete. The active status of multiple lots across various UK regions means there are numerous avenues for participation, making it an attractive prospect for both local and larger-scale pharmaceutical firms aiming to expand their market presence.

## Notice

Transition and 33 % products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).The total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months).

### Lot Information

Transition 2021_1 - 100% Products (All regions)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments

Options: Options to extend (at the Authority's sole discretion) for up to a further 10.5 months.

Transition 2021_1 - CESW region (Transition & 33% products)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments

Options: Options to extend (at the Authority's sole discretion) for up to a further 5.5 months.

Transition 2021_1 - LSNE region (Transition & 33% products)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months)

Options: Options to extend (at the Authority's sole discretion) for up to a further 10.5 months.

Transition 2021_1 - NWLN region (Transition & 33% products)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments

Options: Options to extend (at the Authority's sole discretion) for up to a further 14.5 months.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/009271-2021 |
| Notice type | Award Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large, SME |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 29 Apr 2021 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 17 Mar 2021 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £1 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) |
| Locality | RUNCORN |
| Post town | Warrington |
| Postcode | WA7 2ES |
| Country | England |
| ITL 1 | TLD North West (England) |
| ITL 2 | TLD7 Merseyside |
| ITL 3 | TLD71 East Merseyside |
| Local authority | Halton |
| Electoral ward | Halton Lea |
| Westminster constituency | Runcorn and Helsby |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 20 |
| Supplier names | ACCORD-UK; AMAROX; ASCEND LABORATORIES; ASPEN PHARMA IRELAND; ASPIRE PHARMA; AVENTIS PHARMA LTD T/A SANOFI; BROWN AND BURK; DAY LEWIS MEDICAL; DR.REDDY'S LABORATORIES (UK; KENT PHARMA; MARTINDALE PHARMA; MEDAC PHARMA; MORNINGSIDE PHARMAEUTICALS; PANPHARMA; PFIZER; RANBAXY; SELECTIVE SUPPLIES; TEVA; THORNTON AND ROSS; TILLOMED LABORATORIES |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products
- 33690000 - Various medicinal products

## Release History

- 29 Apr 2021 at 12:43 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/009271-2021

## Notice URLs

- https://ted.europa.eu/udl?uri=TED:NOTICE:578982-2020:TEXT:EN:HTML
- https://www.england.nhs.uk/
- https://www.gov.uk/courts-tribunals

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02aba8. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-02aba8.json.